Quest Vision Inc.
This article was originally published in Start Up
Executive Summary
Quest Vision has developed an intraocular lens that accommodates the way the natural lens does, that is, it changes shape for near or distance vision. Originally designed for cataract patients, the lens will also serve 89 million older Americans suffering from presbyopia.
You may also be interested in...
WaveTec Prepares for a New Wave in Refractive Surgery
Refractive lens exchange is a mega opportunity in ophthalmology with the potential to serve the large patient populations with presbyopia and astigmatism. The category has been slow to take off, however, because current technology doesn't allow clinicians to meet, consistently and with confidence, the high expectations of new refractive surgery customers who are paying out of pocket for the benefit of great vision, at all distances. WaveTec has an enabling technology for a wide range of refractive surgeries to help clinicians and the many manufacturers of implantable intraocular lenses deliver on the promise of better vision.
The Farsightedness of Refractec
Presbyopia is causing a rapprochement between two distinct types of ophthalmic surgeons--the cataract surgeon implanting intraocular lenses in the elderly, and the refractive surgeon offering private-pay laser vision correction procedures to young adults. Bridging the gap is Refractec, the first company to ever get FDA approval for an ophthalmic surgery technology specifically for presbyopia. Refractec offers a non-cutting treatment that surgeons regard as a "starter treatment" that gets new kinds of patients into refractive surgery practices.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.